Ascentage Pharma posted its 2026 interim report on September 17, 2026, covering financial highlights, Business highlights and interim financial statements. Investors can also review management discussion, an independent review report and other information included in the interim announcement.
Key Highlights
- The report describes the 2023 placing as involving 22,500,000 Shares at HK$24.45 per share.
- Ascentage Pharma Group International is a biotechnology company.
- Each ADS represents 4 Ordinary Shares under the report’s definitions.
Interim Report Covers Financial and Business Updates
Ascentage Pharma Group International is a biotechnology company. The report is structured around corporate information, financial highlights, business highlights, management discussion and analysis, and other information. It also contains an independent review report and interim consolidated statements covering profit or loss, comprehensive income or loss, financial position, changes in Equity and cash flows. The document also includes definitions for terms used across Ascentage Pharma’s reporting. Those definitions cover the company, its subsidiaries, share schemes, placing arrangements, products and financial reporting terminology.
Historical Share Transactions Listed
It also describes the 2023 placing as involving 22,500,000 Shares at HK$24.45 per share. The 2025 placing is defined as a placing and subscription of 22,000,000 Shares at HK$68.60 each.
FAQs
Q: What does Ascentage Pharma’s 2026 interim report include?
A: Ascentage Pharma’s interim report includes financial highlights, business highlights, management discussion and interim consolidated financial statements. It also contains notes and an independent review report.
Q: How many shares were involved in Ascentage Pharma’s 2024 share subscription?
A: The 2024 share subscription involved the purchase of 24,307,322 new Shares issued by Ascentage Pharma under its general mandate.
Q: What does one Ascentage Pharma ADS represent?
A: One Ascentage Pharma ADS represents 4 Ordinary Shares. The definition appears among the terms used in the company’s interim report.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.